Ranbaxy Recalls Nitrofurantoin off U.S. Shelves

Recently, Ranbaxy Pharmaceuticals Inc. announced their voluntary recall of all Nitrofurantoin Capsules lot (USP 100 mg capsules), that currently exist on the U.S. market.

Ranbaxy has decided to recall all lots based on product determination that revealed nonconformity with approved laboratory specifications.  Ranbaxy maintains caution and commitment to the health and safety of patients as they continue to investigate the cause of laboratory nonconformity.

The recall is being conducted at the retail level and is in conjunction with FDA coordination.  Ranbaxy, claims that to the best of their knowledge, the product in question does not cause any serious adverse side effects.  However, Ranbaxy has reason to believe that there may be a possibility of non-serious gastrointestinal adverse effects such as nausea and vomiting.  All patients who are currently consuming and/or has been prescribed Nitrofurantoin should consult a doctor for alternative treatment options.